Skip to main
NUVB
NUVB logo

Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio (NUVB) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvation Bio, Inc. is positioned favorably due to its promising pipeline of differentiated oncology therapeutics, including the selective and potent c-ros oncogene 1 (ROS1) inhibitor taletrectinib, which targets the high-need market for ROS1+ non-small cell lung cancer. The company’s clinical candidates, particularly Safusidenib and NUV-868, demonstrate enhanced efficacy and tolerability profiles, with expectations for market expansion given their potential FDA approvals and favorable NCCN guideline inclusion. Additionally, Nuvation Bio's innovative drug-drug conjugate platform offers significant advantages over traditional approaches, enhancing tissue-selective targeting and minimizing off-target toxicity, positioning the company for success in a competitive market exceeding $3 billion.

Bears say

Nuvation Bio Inc faces a challenging outlook primarily due to the declining market share of competing therapies, notably seen in prior instances like PFE's Xalkori, which peaked at $524 million in sales but struggled against second-generation treatments. The company's strategic direction and long-term viability are under scrutiny due to its inability to advance critical clinical assets, which raises concerns about its product pipeline, particularly taletrectinib, amidst increasing competition and potential market saturation. Furthermore, the risks associated with negative clinical data, commercial uptake below expectations, and long-term dilution could significantly impair Nuvation Bio's financial stability and investor confidence.

Nuvation Bio (NUVB) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvation Bio (NUVB) Forecast

Analysts have given Nuvation Bio (NUVB) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Nuvation Bio (NUVB) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvation Bio (NUVB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.